eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2021
vol. 38
 
Share:
Share:
abstract:
Original paper

Analysis of the influence of adalimumab to the expression pattern of mRNA and protein of TGF-β1-3 in dermal fibroblast exposed to lipopolysaccharide

Michał Schweizer
1
,
Iwona Adwent
1
,
Beniamin O. Grabarek
1, 2
,
Dariusz Boroń
1, 3

1.
Department of Histology, Cytophysiology and Embryology, Faculty of Medicine, University of Technology, Katowice, Poland
2.
Department of Clinical Trials, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch, Krakow, Poland
3.
Department of Gynaecology and Obstetrics with Gynaecologic Oncology, Ludwik Rydygier Memorial Specialized Hospital, Krakow, Poland
Adv Dermatol Allergol 2021; XXXVIII (4): 597–602
Online publish date: 2020/04/06
View full text Get citation
 
Introduction
Psoriasis is a inflammatory illness, where incorrect expression of cytokines and bacteria lipopolysaccharide are observed. In the therapy of moderate to severe psoriasis anti-TNF drugs, i.e. adalimumab are used which have the influence for secreting another cytokines, such as transforming growth factor-β (TGF-β).

Aim
The goal of this study was to analyse the expression profile of mRNA TGF-β1-3 and proteins (TGF-β1 and TGF-β2) it codes in normal human dermal fibroblasts (NHDF) exposed to bacterial lipopolysaccharide (induction of inflammation) and adalimumab (anti-TNF drug).

Material and methods
NHDFs treated with bacterial lipopolysaccharide at a medium concentration of 1 µg/ml for 8 h, and then added to an adalimumab culture at a concentration of 8 µg/ml and continued exposure of the fibroblasts to it for 2, 8 and 24 h. The molecular analysis included microarray, RTqPCR and ELISA assays.

Results
Treating the skin fibroblast cells with LPS resulted in significant statistical changes in the expression of TGF-β1 (­) and TGF-β2 (Ż) in comparison to the control culture. Likewise, after adding adalimumab to the culture of NHDF treated previously with LPS, significant changes in the expression of TGF-β1 (­) and TGF-β2 (Ż) were noted in comparison to the control culture (p < 0.05). On the protein level it can be determined that LPS and adalimumab cause an increase in the concentration of TGF-β1 and a decrease in the expression of TGF-β2 in comparison to the control culture.

Conclusions
Blocking the signalling dependant on TNF-α using adalimumab causes an increase in the expression of TGF-β1 and a simultaneous decrease in the case of TGF-β2.

keywords:

transforming growth factor β1–3, adalimumab, LPS, inflammation

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.